Expand PCVX Menu
PCVX MENU

PCVX Latest Press Releases

-- June 2, 2026 --

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults Globe Newswire 4:05 PM

-- May 6, 2026 --

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- April 7, 2026 --

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference Globe Newswire 4:05 PM

-- March 25, 2026 --

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer Globe Newswire 7:30 AM

-- March 23, 2026 --

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Globe Newswire 8:30 AM

-- March 18, 2026 --

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Globe Newswire 7:34 PM

-- February 24, 2026 --

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- February 11, 2026 --

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines Globe Newswire 4:05 PM

-- February 10, 2026 --

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 Globe Newswire 4:05 PM

-- February 5, 2026 --

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes